727-18-4Relevant articles and documents
Compound, liquid crystal composition, liquid crystal display element, and liquid crystal display device
-
Paragraph 0090; 0095-0096; 0112; 0117-0118, (2020/08/01)
The present invention relates to a compound, a liquid crystal composition, a liquid crystal display element, and a liquid crystal display device, wherein the compound is represented by the following formula I, and the liquid crystal composition contains the compound represented by the formula I. According to the present invention, the compound represented by the formula I has advantages of good compatibility with other compounds and good ultraviolet resistance; and the compound as the reactive mesogen (RM) has advantages of good mutual solubility, high polymerization activity (less monomer residue), and strong binding ability, can be separately used as the self-aligning agent of a liquid crystal composition, can further be used as the self-aligning agent for the copolymerization of vertical alignment materials and other RM in PSA (polymer-supported alignment) and PS (polymer-stabilized) mode liquid crystal compositions, and can avoid PI process so as to simplify the process of liquid crystal display elements or liquid crystal displays and improve the production efficiency .
Pharmacophore elucidation of phosphoiodyn A - Potent and selective peroxisome proliferator-activated receptor β/δ agonists with neuroprotective activity
Kinarivala, Nihar,Suh, Ji Ho,Botros, Mina,Webb, Paul,Trippier, Paul C.
supporting information, p. 1889 - 1893 (2016/04/05)
We report the pharmacophore of the peroxisome proliferator-activated receptor δ (PPARδ) agonist natural product phosphoiodyn A is the phosphonate core. Synthesis of simplified phosphonate esters 13 and 15 provide structurally novel, highly selective and potent PPARδ agonists (EC50 = 78 and 112 nM, respectively). Further, both compounds demonstrate significant neuroprotective activity in an in vitro cellular model indicating that phosphonates may be an effective novel scaffold for the design of therapeutics for the treatment of neurodegenerative disorders.
Biosynthesis of natural products with a P-C bond. 7. Synthesis of [1,1-2H2]-, [2,2-2H2]-, (R)- and (S)-[1-2H1](2-hydroxyethyl)phosphonic acid and (R,S)-[1-2H1](1,2-dihydroxyethyl)phosphonic acid and incorporation studies into fosfomycin in Streptomyces fradiae
Hammerschmidt,Kahlig
, p. 2364 - 2370 (2007/10/02)
-